Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Myelodysplastic Syndromes
•
Hematology
How do you approach a patient with CMML requiring platelet transfusions?
Would you consider use of TPO-R agonists such as eltrombopag or romiplostim for a patient like this?
Related Questions
Would you still recommend bone marrow biopsy in an elderly non-transplant eligible patient with mild cytopenias if NGS from peripheral blood indicates MDS mutations?
Is there an advantage to early therapy with hypomethylating agents for high/very high risk patients with MDS who are not transplant candidates and have only mild cytopenias?
What is your approach for choosing between Imetelstat and Luspatercept in managing MDS related anemia?
How would you approach fertility preservation in a young patient with DLBCL requiring R-CHOP?
What are the treatment options for relapsed T-ALL in a patient who was nonadherent with AALL and hyper-CVAD regimens?
What is your preferred second line regimen for follicular lymphoma that has relapsed four years out since receiving BR?
How do you modify Daratumumab-RVD relative to the protocols used in trials when used as a first-line agent to transplant-eligible patients with myeloma?
How would you treat a tDLBCL originally treated with R-CHOP who relapses with DLBCL 15 years after the original diagnosis?
How would one approach concomitant diffuse large B cell lymphoma and fibrotic phase myelofibrosis?
In which patients with essential thrombocythemia would you use ropeginterferon alfa-2b?